Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 1
1(20.0%)
5Total
N/A(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06721975Not ApplicableRecruiting

Thulium Fiber Laser (TFL) vs Thulio Pulsed Thulium:YAG (p-Tm:YAG)

Role: collaborator

NCT04821115Not ApplicableCompleted

Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease

Role: collaborator

NCT03905057Not ApplicableUnknown

Early Shockwave Therapy for Post-RP ED

Role: lead

NCT03039218Not ApplicableTerminated

Dornier Aries 2 Extracorporeal Shock Wave Device for the Treatment of Mild Erectile Dysfunction (ED)

Role: lead

NCT02620982Phase 1Completed

ARIES for Vasculogenic Erectile Dysfunction

Role: lead

All 5 trials loaded